Effects of a Marine Protein Hydrolysate in Healthy Adults
Launched by UNIVERSITY OF BERGEN · Nov 25, 2021
Trial Information
Current as of June 07, 2025
Completed
Keywords
ClinConnect Summary
Marine protein sources, including fish and fish protein hydrolysates, may have particular health benefits. Health benefits from fish consumption have been attributed to the n-3 polyunsaturated fatty acids, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Proteins from marine sources may contain valuable bioactive components, with amino acid composition and protein profiles that differ from terrestrial sources. Generally, the dietary source of protein can affect cellular energy metabolism, and hydrolyzed peptides can have potent and specific bioactive potential.
Res...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Healthy female and male subjects at age 20-80 years old understanding Norwegian oral and written information
- • Waist circumference for males \< 102 cm and females \< 88 cm
- Exclusion Criteria:
- • Pregnancy or lactation
- • Having used high-dose omega-3 PUFA supplements (\>2 g/day) less than 28 days prior to randomization
- • Use of corticosteroids that will influence protein metabolism
- • Antibiotic treatment previous 3 months
- • Alcohol or drug abuse or any conditions associated with poor compliance
- • Medical diagnosis of malabsorption disorders, Crohn's disease, or lactose intolerance
- • Scheduled hospitalization during the course of the study that could compromise the study
- • Diabetes type I or II, serious high blood pressure at screening, serious infections, diseases requiring medication that can influence the study
- • Known or suspected sensitivity or allergic reactions to the IMP or excipients
- • Presence of other major medical or psychiatric illness that would affect the ability to participate in the study or put the subject at increased risk
- • Intake of statins. If needed to obtain the recruitment goals, we will accept people using a low dose of statin
About University Of Bergen
The University of Bergen is a renowned academic institution located in Norway, recognized for its commitment to advancing medical research and education. With a focus on interdisciplinary collaboration, the university engages in innovative clinical trials that aim to improve patient outcomes and enhance healthcare practices. Leveraging its diverse expertise and state-of-the-art facilities, the University of Bergen fosters a dynamic research environment that attracts both national and international partners, ensuring the translation of scientific discoveries into effective clinical applications. The institution is dedicated to maintaining the highest ethical standards and regulatory compliance in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bergen, , Norway
Patients applied
Trial Officials
Rolf K Berge, PhD
Study Director
University of Bergen, Norway
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials